Chinese Journal of Pharmacovigilance ›› 2014, Vol. 11 ›› Issue (6): 358-361.
Previous Articles Next Articles
CUI Xiang-li1, QIU Shuang1, SI Tu-wei1, ZHAO Rui1, WANG Ying1, ZHOU Hong1, HUANG Qian2, GAI Di1, LIU Li-hong1, *
Received:2013-12-24
Revised:2016-02-03
Online:2014-06-08
Published:2016-03-02
CLC Number:
CUI Xiang-li, QIU Shuang, SI Tu-wei, ZHAO Rui, WANG Ying, ZHOU Hong, HUANG Qian, GAI Di, LIU Li-hong. Application Evaluation and Literature Review of Hydroxyethyl Starch 130/0.4 Sodium Chloride Injection in Our Hospital[J]. Chinese Journal of Pharmacovigilance, 2014, 11(6): 358-361.
| [1] Dellinger R P, Levy M M,Rhodes A, et al. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsisand Septic Shock, 2012[J]. Intensive Care Med, 2013, 39(2):165-228. [2] Myburgh J A, Finfer S, Bellomo R, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care[J]. N Engl J Med,2012,367(20): 1901-1911. [3] Perner A, Haase N, Guttormsen A B, et al. Hydroxyethyl starch 130/0.4 versus Ringer's acetate in severe sepsis[J]. N Engl J Med,2012,367(2):124-134. [4] Rioux J P, Lessard M, De Bortoli B, et al. Pentastarch 10% (250 kDa/0.45) is an independent risk factor of acute kidney injury following cardiac surgery[J]. Critical care medicine, 2009,37(4):1293-1298. [5] Lissauer M E, Chi A, Kramer M E, et al. Association of 6% Hetastarch resuscitation with adverse outcomes in critically ill trauma patients[J]. Am J Surgery,2011,202(1):53-58. [6] Schabinski F,Oishi J,Tuche F,et al. Effects of a predominantly hydroxyethyl starch (HES)-based and a predominantly non HES-based fluid therapy on renal function in surgical ICU patients[J].Intensive Care Medicine,2009, 35(9):1539-1547. [7] Navickis R J, Haynes G R, Wilkes M M.Effect of hydroxyethyl starch on bleeding after cardio -pulmonary bypass: a meta-analysis of randomized trials[J]. J ThoracCardiovascSurg, 2012,144(3):223-230. [8] FDA.Public Workshop-Risks and Benefits of Hydroxyethyl Starch Solutions[EB/OL]. (2012-09-06) [2014-05-04].http://www.fda.gov/BiologicsBloodVaccines/NewsEvents/Workshops Meetings Conf-erences /ucm313370.html. [9] 宫本凤, 毕可波, 刘新华,等. 低分子706代血浆致急性肾衰35 例分析[J].滨州医学院学报,1996, 16(4):362. [10] 肖玲.706代血浆致急性肾功能衰竭10例临床分析[J].临床荟萃,2001,16(24):1123-1124. [11] 李文杰,李慧. 羟乙基淀粉的不良反应[J].中国药业,2006,15（3）：76-77. [12] EMA. PRAC confirms that hydroxyethyl-starch solutions（HES） should no longer be used in patients with sepsis or burn injuries or in critically ill patients[EB/OL]. (2013-10-11)[2014-05-04]http://www.ema.europaeu/docs/en_GB/document_library/Press_release /2013/10/WC500151964.pdf. [13] SFDA.羟乙基淀粉40、20氯化钠注射液与肾功能损害.药品不良反应信息通报[EB/OL].(2005-04-18)[2014-05-04].http://www.sfda.gov.cn/WS01/CL0078 /11280.Html. |
| [1] | JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166. |
| [2] | MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin. Drug traceability coding system in China [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172. |
| [3] | ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222. |
| [4] | GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe. Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5. |
| [5] | MA Li’na, HU Xiaozhen, ZHENG Changhui, SUN Ying, ZHAO Xu, CAO Junling, XIAO Xiaohe. Visual analysis of knowledge map of toxic Chinese medicine Changshan toxicity-effect transformation based the thought of “yin du wei neng” [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 25-32. |
| [6] | LIU Min, CHEN Yan, LIU Wendong, WANG Haixue. Updates and reflections on expedited reporting of safety information during drug clinical trials [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101. |
| [7] | TIAN Chunhua, WU Guizhi. Implementation of periodic benefit risk evaluation reports in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1382-1384. |
| [8] | ZHAO Yan, LI Yao, SONG Ya’na, ZHENG Lijia, LI Dong, ZHAO Yifei, BIAN Rongrong, DONG Fang. Post-marketing active monitoring of medical devices under vigilance [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1385-1390. |
| [9] | PANG Yu, LIU Bo, WU Wenyu, TIAN Yuejie, WANG Tao. Establishment of patient reporting scheme in the UK and its implications [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1259-1263. |
| [10] | WU Yunxiao, YU Yuelin, WANG Shengfeng, SUN Feng, MENG Ruogu, ZHAN Siyan. Suitability assessment of real-world data in active post-marketing surveillance of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1081-1089. |
| [11] | JIA Jinsheng, WANG Qing, LIU Hongliang, HOU Yongfang. Evaluation index system of MAH pharmacovigilance work [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1090-1094. |
| [12] | LIU Hongliang, WANG Qing, HOU Yongfang. Design and implementation of polypharmacy risk data management platform for common diseases of the elderly based on real world data [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1095-1098. |
| [13] | XIA Xudong, LI Meixia, SUN Yang, YANG Shengya. Processes of remote inspection of pharmacovigilance for marketing authorization holders [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 967-970. |
| [14] | LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977. |
| [15] | SHEN Yanjie, WU Yiqing. Management of adverse events during clinical trials [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
